NEXIEN BIOPHARMA, INC.: 10-Q filed 2022-02-08
What NEXIEN BIOPHARMA, INC. reported in its quarterly report filed 2022-02-08 (fiscal Q2 2022): 14 published measures, 37 facts as tagged in accession 0001493152-22-003407.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-02-08
- Fiscal period
- fiscal Q2 2022
- Accession
- 0001493152-22-003407 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All NEXIEN BIOPHARMA, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 2,942 | USD | |
| At 2021-06-30 | 25,541 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -62,425 | USD | |
| At 2021-06-30 | -13,775 | USD | |
| At 2020-12-31 | 23,557 | USD | |
| At 2020-06-30 | -6,365 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | -220,194 | USD | 92 |
| 2021-07-01 to 2021-12-31 | -341,905 | USD | 184 |
| 2020-10-01 to 2020-12-31 | -828,031 | USD | 92 |
| 2020-07-01 to 2020-12-31 | -1,889,451 | USD | 184 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-12-31 | -30,099 | USD | 184 |
| 2020-07-01 to 2020-12-31 | -40,652 | USD | 184 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-07-01 to 2021-12-31 | 15,000 | USD | 184 |
| 2020-07-01 to 2020-12-31 | 78,000 | USD | 184 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | -10,649,006 | USD | |
| At 2021-06-30 | -10,307,101 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-12-31 | 534,220 | USD | 184 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 2,942 | USD | |
| At 2021-06-30 | 25,541 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 65,367 | USD | |
| At 2021-06-30 | 39,316 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | 213,496 | USD | 92 |
| 2021-07-01 to 2021-12-31 | 328,435 | USD | 184 |
| 2020-10-01 to 2020-12-31 | 826,198 | USD | 92 |
| 2020-07-01 to 2020-12-31 | 1,887,490 | USD | 184 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 56,772,196 | shares | |
| At 2021-06-30 | 55,772,196 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-12-31 | 10,545,904 | USD | |
| At 2021-06-30 | 10,476,004 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | 202,056 | USD | 92 |
| 2021-07-01 to 2021-12-31 | 310,955 | USD | 184 |
| 2020-10-01 to 2020-12-31 | 818,798 | USD | 92 |
| 2020-07-01 to 2020-12-31 | 1,864,500 | USD | 184 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2021-12-31 | -6,698 | USD | 92 |
| 2021-07-01 to 2021-12-31 | -13,470 | USD | 184 |
| 2020-10-01 to 2020-12-31 | -1,833 | USD | 92 |
| 2020-07-01 to 2020-12-31 | -1,961 | USD | 184 |
Inspect the source
- Entity
- NEXIEN BIOPHARMA, INC. / CIK 0001625288
- Captured
- 2026-09-21T17:21:50.748Z
- SEC response SHA-256
044a00232373cfad706e13d40a0fcc524943f52c3deb14bbc85e1072ff58fe5c
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001625288.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))